Ellevest Inc’s Coherus Oncology CHRS Stock Holding History

Ellevest Inc’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-433	Closed	-$6K	–	1431
2022 Q1	$6K	Sell	433 -43	-9%	-$547	﹤0.01%	973
2021 Q4	$8K	Sell	476 -13	-3%	-$227	﹤0.01%	893
2021 Q3	$8K	Buy	+489	New	+$7.17K	﹤0.01%	857

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ellevest Inc's CHRS Position: Q2 2022 in Review

Ellevest Inc sold out of Coherus Oncology (CHRS) in Q2 2022, closing a stake of 433 shares — an estimated $6K sold.

Ellevest Inc first reported a position in CHRS in Q3 2021 and held it in 3 quarters. The position peaked at $8K in Q4 2021. 176 funds tracked by Wall St. Rank hold CHRS as of Q2 2022.

Ellevest Inc reported no remaining Coherus Oncology position as of Q2 2022 after selling out during the quarter.
Ellevest Inc sold 433 Coherus Oncology shares in Q2 2022, an estimated $6K.
Ellevest Inc first reported a position in Coherus Oncology in Q3 2021 and held it in 3 quarters.
Ellevest Inc's Coherus Oncology position peaked at $8K in Q4 2021.
176 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2022.

Based on Ellevest Inc's 13F filing for Q2 2022, filed 18 Jul 2022.